Deals
AstraZeneca’s Soriot Asks for Patience as Pfizer Return Looms
This article is for subscribers only.
AstraZeneca Plc Chief Executive Officer Pascal Soriot asked investors for patience with his growth strategy as he outlined drug development plans a week before Pfizer Inc. is allowed to make another takeover attempt.
The U.K. drugmaker remains committed to increasing revenue 75 percent to $45 billion by 2023, Soriot said at a presentation for investors today. AstraZeneca rebuffed a $117 billion offer from Pfizer in May, saying the bid undervalued its drug pipeline.